Skip to main contentSkip to navigationSkip to search

Press releases and news

2024

Camurus announces FDA acceptance of NDA submission for Oclaiz™ for treatment of acromegaly

Camurus’ Full Year Report 2023

Camurus appoints Behshad Sheldon as President of Camurus Inc.

Completed enrollment in the POSITANO study of CAM2029 in patients with polycystic liver disease

Change in number of shares and votes in Camurus

Camurus has carried out a directed share issue of 2,000,000 shares at a subscription price of SEK 545 per share, raising gross proceeds of SEK 1,090 million

Camurus intends to carry out a directed share issue of approximately 2 million shares and provides preliminary financial information for FY 2023

2023

Change in number of shares and votes in Camurus

Camurus submits New Drug Application to the US FDA for Oclaiz™ for treatment of acromegaly

Camurus to enter Large Cap segment on Nasdaq Stockholm

Camurus announces completed enrollment in the Phase 3 SORENTO study of CAM2029 in patients with neuroendocrine tumors

Camurus’ Interim Report Third Quarter 2023

Camurus receives improved ESG risk rating by Sustainalytics

Camurus to present at Jefferies 2023 Healthcare Conference London

Camurus raises financial guidance for the full year 2023

Camurus’ Nomination Committee appointed for the Annual General Meeting 2024

Camurus establishes new, sustainable headquarters and laboratories in Science Village, Lund

Camurus announces US launch of Brixadi™ for the treatment of moderate to severe opioid use disorder by Braeburn

Change in number of shares and votes in Camurus

Exercise of Camurus’ subscription warrant program 2020/2023

Load more press releases

Subscribe

Get the latest news from Camurus

Subscribe to receive latest news from Camurus directly to your email. 

Information types

By subscribing to news from Camurus, you agree to our privacy policy.

Thank you. You will get an e-mail message to activate your subscription.